These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24938413)

  • 1. Small molecules that target the toxic RNA in myotonic dystrophy type 2.
    Nguyen L; Lee J; Wong CH; Zimmerman SC
    ChemMedChem; 2014 Nov; 9(11):2455-62. PubMed ID: 24938413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2).
    Wong CH; Fu Y; Ramisetty SR; Baranger AM; Zimmerman SC
    Nucleic Acids Res; 2011 Nov; 39(20):8881-90. PubMed ID: 21768123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.
    Sellier C; Cerro-Herreros E; Blatter M; Freyermuth F; Gaucherot A; Ruffenach F; Sarkar P; Puymirat J; Udd B; Day JW; Meola G; Bassez G; Fujimura H; Takahashi MP; Schoser B; Furling D; Artero R; Allain FHT; Llamusi B; Charlet-Berguerand N
    Nat Commun; 2018 May; 9(1):2009. PubMed ID: 29789616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
    Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
    J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
    Schneider-Gold C; Timchenko LT
    Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.
    Benhamou RI; Angelbello AJ; Wang ET; Disney MD
    Cell Chem Biol; 2020 Feb; 27(2):223-231.e4. PubMed ID: 31981476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study.
    Perdoni F; Malatesta M; Cardani R; Giagnacovo M; Mancinelli E; Meola G; Pellicciari C
    Eur J Histochem; 2009 Sep; 53(3):e18. PubMed ID: 19864209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.
    Jones K; Jin B; Iakova P; Huichalaf C; Sarkar P; Schneider-Gold C; Schoser B; Meola G; Shyu AB; Timchenko N; Timchenko L
    Am J Pathol; 2011 Nov; 179(5):2475-89. PubMed ID: 21889481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic mechanisms of myotonic dystrophy.
    Lee JE; Cooper TA
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1281-6. PubMed ID: 19909263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1).
    Gareiss PC; Sobczak K; McNaughton BR; Palde PB; Thornton CA; Miller BL
    J Am Chem Soc; 2008 Dec; 130(48):16254-61. PubMed ID: 18998634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
    Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G
    Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2.
    Cardani R; Baldassa S; Botta A; Rinaldi F; Novelli G; Mancinelli E; Meola G
    Neuromuscul Disord; 2009 May; 19(5):335-43. PubMed ID: 19345584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fly model for the CCUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1.
    Yu Z; Goodman LD; Shieh SY; Min M; Teng X; Zhu Y; Bonini NM
    Hum Mol Genet; 2015 Feb; 24(4):954-62. PubMed ID: 25305073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudouridine Modification Inhibits Muscleblind-like 1 (MBNL1) Binding to CCUG Repeats and Minimally Structured RNA through Reduced RNA Flexibility.
    deLorimier E; Hinman MN; Copperman J; Datta K; Guenza M; Berglund JA
    J Biol Chem; 2017 Mar; 292(10):4350-4357. PubMed ID: 28130447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.
    Sammons MA; Antons AK; Bendjennat M; Udd B; Krahe R; Link AJ
    PLoS One; 2010 Feb; 5(2):e9301. PubMed ID: 20174632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats.
    Kino Y; Mori D; Oma Y; Takeshita Y; Sasagawa N; Ishiura S
    Hum Mol Genet; 2004 Mar; 13(5):495-507. PubMed ID: 14722159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways.
    Wagner-Griffin S; Abe M; Benhamou RI; Angelbello AJ; Vishnu K; Chen JL; Childs-Disney JL; Disney MD
    J Med Chem; 2021 Jun; 64(12):8474-8485. PubMed ID: 34101465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Specific Cleavage of an RNA Repeat Expansion with a Dimeric Small Molecule Is Advantageous over Sequence-Specific Recognition by an Oligonucleotide.
    Benhamou RI; Angelbello AJ; Andrews RJ; Wang ET; Moss WN; Disney MD
    ACS Chem Biol; 2020 Feb; 15(2):485-493. PubMed ID: 31927948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
    Timchenko L
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.
    Zu T; Cleary JD; Liu Y; Bañez-Coronel M; Bubenik JL; Ayhan F; Ashizawa T; Xia G; Clark HB; Yachnis AT; Swanson MS; Ranum LPW
    Neuron; 2017 Sep; 95(6):1292-1305.e5. PubMed ID: 28910618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.